ETFs AstraZeneca PLC NYSE

AZN

US0463531089

Name	YTD change	Weight	AuM
INVESCO QQQ ETF - USD	+14.69%	-.--%	334,922 M€
BMO NASDAQ 100 EQUITY INDEX ETF - CAD HEDGED	+12.88%	-.--%	2,210 M€
DIMENSIONAL INTERNATIONAL SUSTAINABILITY CORE 1 ETF - USD	+7.48%	-.--%	1,193 M€
BMO NASDAQ 100 EQUITY INDEX ETF - CAD	+16.28%	-.--%	1,646 M€
AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF - USD	+0.29%	4.85%	5 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+20.61%	4.05%	81 M€
GLOBAL X AGING POPULATION ETF - USD	+2.77%	3.39%	94 M€
GLOBAL X ACTIVE GLOBAL DIVIDEND ETF - CAD	+11.25%	1.83%	331 M€
SP FUNDS S&P WORLD (EX-US) ETF - USD	+18.57%	1.5%	210 M€
FIRST TRUST WCM INTERNATIONAL EQUITY ETF - USD	+13.35%	1.29%	1,882 M€
FIDELITY FUNDAMENTAL LARGE CAP VALUE ETF - USD	+17.05%	1.15%	19 M€
DIMENSIONAL INTERNATIONAL HIGH PROFITABILITY ETF - USD	+8.38%	1.12%	6,576 M€
INVESCO NASDAQ-100 EQUAL WEIGHT UCITS ETF ACC - USD	+15.49%	1.06%	122 M€
ISHARES HEALTH INNOVATION ACTIVE ETF - USD	+9.88%	1%	13 M€
FIRST TRUST VALUE LINE DIVIDEND INDEX UCITS ETF CLASS A ACCU - USD	+6.31%	0.62%	8 M€
AVANTIS RESPONSIBLE INTERNATIONAL EQUITY ETF - USD	+8.65%	0.54%	361 M€
FIRST TRUST VALUE LINE DIVIDEND ETF - USD	+6.36%	0.42%	8,285 M€
GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF - USD	+5.35%	0.31%	5,369 M€
INVESCO EQQQ NASDAQ-100 UCITS ETF - EUR HEDGED	+11.67%	0.3%	630 M€
INVESCO NASDAQ-100 ESG UCITS ETF - ACC - USD	+17.05%	0.3%	2,914 M€
GLOBAL X NASDAQ 100 RISK MANAGED INCOME ETF - USD	-5.34%	0.3%	15 M€
UBS NASDAQ-100 UCITS ETF CLASS (USD) A-DIS - USD	+15.54%	0.3%	38 M€
MACKENZIE NASDAQ 100 INDEX ETF	+15.76%	0.3%	100 M€
BNP PARIBAS EASY II NASDAQ 100 UCITS ETF - EUR HEDGED	+11.90%	0.3%	16 M€
PACER CASH COWZ 100-NASDAQ 100 ROTATOR ETF - USD	+15.85%	0.29%	40 M€
AMOVA LISTED INDEX FUND U.S. EQUITY NASDAQ100 ETF - JPY	+12.84%	0.29%	115 M€
ISHARES NASDAQ 100 INDEX ETF - CAD	+16.04%	0.29%	138 M€
NEOS NASDAQ 100 HIGH INCOME ETF - USD	+0.06%	0.28%	13,961 M€
ISHARES NASDAQ-100 UCITS ETF (DE) - USD	+15.59%	0.27%	6,226 M€

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).

Employees

96,100

Sector

Pharmaceuticals

Calendar

10-30 Earnings release - Q3 2026

More about the company